Federated Hermes, Inc. Cel Sci Corp Transaction History

Federated Hermes, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 12, 2020	SELL	$11.69 - $14.54 $3,600 - $4,478	-308 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$9.75 - $17.6 $3,003 - $5,420	308 New	308 $5,000
Q1 2020 May 13, 2020	SELL	$7.54 - $17.05 $75 - $170	-10 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$6.71 - $9.55 $73,306 - $104,333	-10,925 Reduced 99.91%	10 $1,000
Q3 2019 Nov 14, 2019	BUY	$6.0 - $9.6 $61,974 - $99,158	10,329 Added 1704.46%	10,935 $98,000
Q2 2019 Aug 14, 2019	BUY	$3.77 - $8.67 $2,284 - $5,254	606 New	606 $5,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.